Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2180 studies found for:    Open Studies | "Breast Neoplasms"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Breast Neoplasms"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Investigation of Three Approaches to Address Fear of Recurrence Among Breast Cancer Survivors
Conditions: Breast Neoplasms;   Breast Cancer;   Breast Carcinoma;   Malignant Neoplasm of Breast;   Cancer of Breast;   Mammary Neoplasm, Human;   Human Mammary Carcinoma;   Malignant Tumor of Breast;   Mammary Cancer;   Mammary Carcinoma;   Anxiety;   Fear;   Neoplasm Remission, Spontaneous;   Spontaneous Neoplasm Regression;   Regression, Spontaneous Neoplasm;   Remission, Spontaneous Neoplasm;   Spontaneous Neoplasm Remission
Interventions: Behavioral: Acceptance and Commitment Therapy;   Behavioral: Survivorship Education;   Behavioral: Usual Care
2 Recruiting A Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients With Advanced Breast Cancer
Conditions: Cancer of the Breast;   Breast Cancer;   Advanced Breast Cancer;   Metastatic Breast Cancer;   Male Breast Cancer;   Triple Negative Breast Cancer;   ER+ Breast Cancer
Interventions: Drug: Female AR(+) TNBC Enzalutamide Naïve;   Drug: Female AR(+) TNBC Enzalutamide Treated;   Drug: Female ER(+) BC Patients;   Drug: Male ER(+) BC Patients
3 Not yet recruiting A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer
Conditions: Breast Cancer;   Triple Negative Breast Neoplasms;   Triple-Negative Breast Neoplasm;   Triple-Negative Breast Cancer;   Triple Negative Breast Cancer;   ER-Negative PR-Negative HER2-Negative Breast Neoplasms;   ER-Negative PR-Negative HER2-Negative Breast Cancer
Interventions: Biological: Bavituximab;   Drug: Taxane
4 Recruiting Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
Conditions: Breast Cancer;   Breast Neoplasm;   Breast Tumor;   Cancer of the Breast
Intervention: Radiation: Proton Radiotherapy
5 Recruiting Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer Patients Who Have Failed an Anthracycline (CAT)
Conditions: Breast Neoplasms;   Breast Cancer
Interventions: Drug: Taxane;   Drug: Taxotere;   Drug: Abraxane;   Drug: Ixabepilone
6 Recruiting Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer
Conditions: Breast Neoplasms;   Malignant Tumor of the Breast
Interventions: Drug: Trastuzumab;   Drug: Pertuzumab;   Drug: Vinorelbine, Paclitaxel, Nab-Paclitaxel , Docetaxel, Capecitabine
7 Not yet recruiting Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
Conditions: Breast Cancer;   Ductal Carcinoma;   Invasive Breast Carcinoma;   Invasive Ductal Breast Carcinoma
Interventions: Biological: Talimogene laherparepvec;   Drug: Paclitaxel
8 Not yet recruiting A Breast Cancer Treatment Decision Aid for Women Aged 70 and Older
Conditions: Breast Cancer;   Estrogen Receptor Positive Breast Cancer;   Node-negative Breast Cancer;   Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Interventions: Other: Breast Cancer Treatment Decision Aid for women 70+;   Other: Usual Care
9 Recruiting Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer
Conditions: Breast Cancer;   Node-positive Breast Cancer;   Breast Adenocarcinoma;   Invasive Breast Carcinoma;   Lobular Breast Carcinoma In Situ
Interventions: Radiation: External Beam Radiation Therapy;   Other: Questionnaire Administration;   Other: Laboratory Biomarker Analysis
10 Recruiting Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer
Conditions: Metastatic Breast Cancer;   Breast Carcinoma;   HER-2 Positive Breast Cancer
Interventions: Drug: Ruxolitinib;   Drug: Trastuzumab
11 Recruiting Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR
Conditions: Breast Neoplasms;   Triple Negative Breast Neoplasms
Interventions: Drug: Dasatinib;   Procedure: Conventional Surgery;   Other: Laboratory Biomarker Analysis
12 Recruiting Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer
Conditions: Breast Cancer;   Breast Carcinoma;   Breast Tumors;   Malignant Neoplasm of Breast
Interventions: Drug: Paclitaxel;   Drug: Alisertib
13 Recruiting Bright Light on Fatigue in Women Being Treated for Breast Cancer
Conditions: Breast Neoplasms;   Breast Cancer;   Cancer of Breast;   Cancer of the Breast
Interventions: Other: Bright blue-green light using light visor cap;   Other: Dim red light using light visor cap;   Other: European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire;   Other: Epworth Sleepiness Scale;   Other: Pittsburgh Sleep Quality Index;   Other: Patient-Reported Outcomes Measurement Information System (PROMIS)-Sleep Disturbance;   Other: Patient-Reported Outcomes Measurement Information System (PROMIS)-Cancer-Fatigue;   Device: Digital foot candle datalogging light meter (Extech Instrument, Model SDL400);   Device: Polysomnography (Easy Ambulatory 2 Cadwell, Kennewick, WA);   Other: Horne-Ostberg Morningness-Eveningness Questionnaire;   Other: Daily Fatigue and Sleep Log
14 Recruiting Proton Radiation for Stage II/III Breast Cancer
Conditions: Breast Cancer;   Breast Neoplasm;   Breast Tumor;   Cancer of the Breast
Intervention: Radiation: Proton Radiotherapy
15 Recruiting Intensity Modulated Accelerated Partial Breast Irradiation Before Surgery in Treating Older Patients With Hormone Responsive Stage 0-I Breast Cancer
Conditions: Ductal Breast Carcinoma in Situ;   Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   Invasive Ductal Breast Carcinoma;   Invasive Ductal Breast Carcinoma With Predominant Intraductal Component;   Lobular Breast Carcinoma in Situ;   Medullary Ductal Breast Carcinoma With Lymphocytic Infiltrate;   Mucinous Ductal Breast Carcinoma;   Papillary Ductal Breast Carcinoma;   Progesterone Receptor-positive Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Tubular Ductal Breast Carcinoma
Interventions: Radiation: accelerated partial breast irradiation;   Radiation: intensity-modulated radiation therapy;   Radiation: image-guided radiation therapy;   Procedure: therapeutic conventional surgery;   Other: questionnaire administration;   Other: laboratory biomarker analysis
16 Not yet recruiting Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
Conditions: Breast Cancer;   Cancer of Breast;   Breast Neoplasms;   Cancer of the Breast
Interventions: Device: Oncotype DX® Breast Cancer Assay;   Behavioral: FACT-B;   Drug: Goserelin;   Drug: Anastrozole;   Drug: Exemestane;   Drug: Fulvestrant;   Drug: Tamoxifen
17 Recruiting Study of Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer
Conditions: Breast Cancer;   Metastatic Breast Cancer;   Recurrent Breast Cancer
Interventions: Drug: Pemetrexed;   Drug: Sorafenib
18 Recruiting Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy
Conditions: Triple Negative Breast Cancer;   Triple-Negative Breast Cancer;   Triple Negative Breast Neoplasms
Intervention: Biological: Personalized polyepitope DNA vaccine
19 Recruiting Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
Conditions: Triple Negative Breast Cancer;   Triple Negative Breast Neoplasms;   Triple-Negative Breast Cancer
Interventions: Biological: Personalized synthetic long peptide vaccine (Poly ICLC);   Drug: Poly ICLC
20 Not yet recruiting Multimodality Breast Imaging for the Assessment of Tumor Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Patients
Conditions: Breast Cancer;   Malignant Neoplasm of Breast
Interventions: Procedure: Dynamic Contrast Enhanced Molecular Resonance Imaging (DCE-MRI);   Procedure: Tc99m Sestamibi Molecular Breast Imaging (MBI);   Drug: 99mTc Sestamibi

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years